{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-003203","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.437468+00:00","generated_at":"2026-05-15T04:11:50.950465+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Xenetic Biosciences grants 100,000 restricted shares to Interim CEO James Parslow","bullets":["Grant of 100,000 restricted shares to James Parslow, Interim CEO and CFO.","7,000 shares vest immediately; 31,000 vest on each of 1st, 2nd, 3rd anniversaries of April 21, 2026.","All unvested shares accelerate upon a Change in Control.","Award is under Amended and Restated Equity Incentive Plan; grant agreement filed as Exhibit 10.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003203","json":"https://secwatch.observer/filing/0001683168-26-003203.json","markdown":"https://secwatch.observer/filing/0001683168-26-003203.md","text":"https://secwatch.observer/filing/0001683168-26-003203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826003203/0001683168-26-003203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826003203/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:11:50.950465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}